logo
Share SHARE
FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of social network company Twitter Inc. (TWTR), jumped over 5 percent on Wednesday, after one of its cofounders Ev Williams dropped a hint during a television interview about the company's sale. Ev Williams, a Twitter cofounder and board member, was asked by Bloomberg TV about the company's... Mazda Motor Corp. (MZDAF.PK) is recalling over 190,000 CX-7 sport utility vehicles to fix a issue that could lead to loss of steering control. The recall involves CX-7 models from 2007 through 2012 manufactured between February 14, 2006 to May 9, 2012. The company said there have been no reports of... Over 68 million email address and passwords of Dropbox users were stolen by hackers, according to a report from Motherboard. Although, the account details were stolen during a previously disclosed breach that took place in 2012, the magnitude of the attack has come to light only now. Following...
comments powered by Disqus
Follow RTT